696 related articles for article (PubMed ID: 19710033)
41. Catholic university experience with molecular adsorbent recycling system in patients with severe liver failure.
Di Campli C; Santoro MC; Gaspari R; Merra G; Zileri Dal Verme L; Zocco MA; Piscaglia AC; Di Gioacchino G; Novi M; Santoliquido A; Flore R; Tondi P; Proietti R; Gasbarrini G; Pola P; Gasbarrini A
Transplant Proc; 2005; 37(6):2547-50. PubMed ID: 16182739
[TBL] [Abstract][Full Text] [Related]
42. Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis.
Salerno F; Guevara M; Bernardi M; Moreau R; Wong F; Angeli P; Garcia-Tsao G; Lee SS
Liver Int; 2010 Aug; 30(7):937-47. PubMed ID: 20492521
[TBL] [Abstract][Full Text] [Related]
43. [Hepatorenal syndrome].
Pŭrvanov P
Khirurgiia (Sofiia); 2002; 58(2):34-9. PubMed ID: 12515019
[TBL] [Abstract][Full Text] [Related]
44. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome.
Krag A; Møller S; Henriksen JH; Holstein-Rathlou NH; Larsen FS; Bendtsen F
Hepatology; 2007 Dec; 46(6):1863-71. PubMed ID: 18027874
[TBL] [Abstract][Full Text] [Related]
45. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems.
Guevara M; Ginès P; Bandi JC; Gilabert R; Sort P; Jiménez W; Garcia-Pagan JC; Bosch J; Arroyo V; Rodés J
Hepatology; 1998 Aug; 28(2):416-22. PubMed ID: 9696006
[TBL] [Abstract][Full Text] [Related]
46. [Therapy of hepatorenal syndrome].
Walter E
Praxis (Bern 1994); 1997 Jan; 86(4):102-3. PubMed ID: 9064719
[TBL] [Abstract][Full Text] [Related]
47. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond.
Moreau R; Lebrec D
Hepatology; 2006 Mar; 43(3):385-94. PubMed ID: 16496352
[TBL] [Abstract][Full Text] [Related]
48. Effects of plasma expansion with albumin and paracentesis on haemodynamics and kidney function in critically ill cirrhotic patients with tense ascites and hepatorenal syndrome: a prospective uncontrolled trial.
Umgelter A; Reindl W; Wagner KS; Franzen M; Stock K; Schmid RM; Huber W
Crit Care; 2008; 12(1):R4. PubMed ID: 18197961
[TBL] [Abstract][Full Text] [Related]
49. Renal failure in patients with cirrhosis: hepatorenal syndrome and renal support strategies.
Meltzer J; Brentjens TE
Curr Opin Anaesthesiol; 2010 Apr; 23(2):139-44. PubMed ID: 20124895
[TBL] [Abstract][Full Text] [Related]
50. Hepatorenal syndrome.
Guevara M; Ginès P
Dig Dis; 2005; 23(1):47-55. PubMed ID: 15920325
[TBL] [Abstract][Full Text] [Related]
51. Impact of molecular adsorbent recirculating system on renal recovery in type-1 hepatorenal syndrome patients with chronic liver failure.
Lavayssière L; Kallab S; Cardeau-Desangles I; Nogier MB; Cointault O; Barange K; Muscari F; Rostaing L; Kamar N
J Gastroenterol Hepatol; 2013 Jun; 28(6):1019-24. PubMed ID: 23425070
[TBL] [Abstract][Full Text] [Related]
52. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial.
Bañares R; Nevens F; Larsen FS; Jalan R; Albillos A; Dollinger M; Saliba F; Sauerbruch T; Klammt S; Ockenga J; Pares A; Wendon J; Brünnler T; Kramer L; Mathurin P; de la Mata M; Gasbarrini A; Müllhaupt B; Wilmer A; Laleman W; Eefsen M; Sen S; Zipprich A; Tenorio T; Pavesi M; Schmidt HH; Mitzner S; Williams R; Arroyo V;
Hepatology; 2013 Mar; 57(3):1153-62. PubMed ID: 23213075
[TBL] [Abstract][Full Text] [Related]
53. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
Boyer TD; Sanyal AJ; Wong F; Frederick RT; Lake JR; O'Leary JG; Ganger D; Jamil K; Pappas SC;
Gastroenterology; 2016 Jun; 150(7):1579-1589.e2. PubMed ID: 26896734
[TBL] [Abstract][Full Text] [Related]
54. Comparison of midodrine and albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients: a randomized pilot study.
Hamdy H; ElBaz AA; Hassan A; Hassanin O
J Clin Gastroenterol; 2014 Feb; 48(2):184-8. PubMed ID: 23842215
[TBL] [Abstract][Full Text] [Related]
55. Acute systemic, splanchnic and renal haemodynamic changes induced by molecular adsorbent recirculating system (MARS) treatment in patients with end-stage cirrhosis.
Donati G; Piscaglia F; Colì L; Silvagni E; Righini R; Donati G; Pini P; Stefoni S; Bolondi L
Aliment Pharmacol Ther; 2007 Sep; 26(5):717-26. PubMed ID: 17697205
[TBL] [Abstract][Full Text] [Related]
56. Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study.
Ghosh S; Choudhary NS; Sharma AK; Singh B; Kumar P; Agarwal R; Sharma N; Bhalla A; Chawla YK; Singh V
Liver Int; 2013 Sep; 33(8):1187-93. PubMed ID: 23601499
[TBL] [Abstract][Full Text] [Related]
57. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study.
Mulkay JP; Louis H; Donckier V; Bourgeois N; Adler M; Deviere J; Le Moine O
Acta Gastroenterol Belg; 2001; 64(1):15-9. PubMed ID: 11322061
[TBL] [Abstract][Full Text] [Related]
58. Pathophysiology of Hepatorenal Syndrome.
Velez JCQ; Latt N; Rodby RA
Adv Kidney Dis Health; 2024 Mar; 31(2):87-99. PubMed ID: 38649221
[TBL] [Abstract][Full Text] [Related]
59. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites.
Krag A; Bendtsen F; Henriksen JH; Møller S
Gut; 2010 Jan; 59(1):105-10. PubMed ID: 19837678
[TBL] [Abstract][Full Text] [Related]
60. Vasoconstrictor use in liver transplantation: is there evidence for rational use?
Skagen CL; Said A
Minerva Gastroenterol Dietol; 2010 Sep; 56(3):279-96. PubMed ID: 21037546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
